- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Submit a Manuscript
- Table of Contents
Volume 2012 (2012), Article ID 215692, 5 pages
The Risk Factors for Nosocomial Infection in Chinese Patients with Active Rheumatoid Arthritis in Shanghai
1Department of Rheumatology and Immunology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
2Department of Rheumatology and Immunology, Shanghai Guanghua Hospital, Shanghai 200052, China
3Department of Rheumatology and Immunology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
4Department of Rheumatology and Immunology, Shanghai Longhua Hospital, Shanghai 200032, China
5Department of Rheumatology and Immunology, Yueyang Hospital of Integrated Traditional and Western Medicine, Shanghai 200473, China
6Department of Rheumatology and Immunology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai 200071, China
7Department of Rheumatology and Immunology, Shanghai First People's Hospital, Shanghai 201620, China
8Department of Rheumatology and Immunology, Shidong Hospital, Shanghai 200438, China
9Department of Rheumatology and Immunology, No.3 People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201900, China
10Department of Rheumatology and Immunology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
11Department of Rheumatology and Immunology, Huashan Hospital, Shanghai 200040, China
12Department of Rheumatology and Immunology, Renji Hospital, Shanghai 200003, China
13Department of Immunology and Rheumatology, Huadong Hospital, Fudan University, Yananxi Road, Shanghai 200040, China
Received 7 December 2011; Accepted 15 January 2012
Academic Editors: A. Adebajo, A. H. Gerards, and A. Kessel
Copyright © 2012 Wei-Lin Xie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. Bernatsky, M. Hudson, and S. Suissa, “Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis,” Rheumatology, vol. 46, no. 7, pp. 1157–1160, 2007.
- T. A. Simon, J. Askling, D. Lacaille et al., “Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment,” Arthritis Research & Therapy, vol. 12, no. 2, article R67, 2010.
- A. L. Smitten, H. K. Choi, M. C. Hochberg et al., “The risk of hospitalized infection in patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 35, no. 3, pp. 387–393, 2008.
- D. M. Hacek, T. Suriano, G. A. Noskin, J. Kruszynski, B. Reisberg, and L. R. Peterson, “Medical and economic benefit of a comprehensive infection control program that includes routine determination of microbial clonality,” American Journal of Clinical Pathology, vol. 111, no. 5, pp. 647–654, 1999.
- D. W. Spelman, “Hospital-acquired infections,” Medical Journal of Australia, vol. 176, no. 6, pp. 286–291, 2002.
- F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 31, no. 3, pp. 315–324, 1988.
- M. L. L. Prevoo, M. A. van 't Hof, H. H. Kuper, M. A. van Leeuwen, L. B. A. van de Putte, and P. L. C. M. van Riel, “Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 38, no. 1, pp. 44–48, 1995.
- J. S. Garner, W. R. Jarvis, T. G. Emori, T. C. Horan, and J. M. Hughes, “CDC definitions for nosocomial infections,” in APIC Infection Control and Applied Epidemiology: Principles and Practice, R. N. Olmsted, Ed., pp. A-1–A-20, Mosby, St. Louis, Mo, USA, 1996.
- A. von Graevenitz, “The role of opportunistic bacteria in human disease,” Annual Review of Microbiology, vol. 31, pp. 447–471, 1977.
- M. F. Doran, C. S. Crowson, G. R. Pond, W. M. O'Fallon, and S. E. Gabriel, “Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study,” Arthritis and Rheumatism, vol. 46, no. 9, pp. 2287–2293, 2002.
- J. J. Goronzy and C. M. Weyand, “Rheumatoid arthritis,” Immunological Reviews, vol. 204, pp. 55–73, 2005.
- J. R. Curtis, N. Patkar, A. Xie et al., “Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists,” Arthritis and Rheumatism, vol. 56, no. 4, pp. 1125–1133, 2007.
- G. Geri, S. Dadoun, T. Bui et al., “Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases,” BMC Infectious Diseases, vol. 11, article 304, 2011.
- J. M. Kahlenberg and D. A. Fox, “Advances in the medical treatment of rheumatoid arthritis,” Hand Clinics, vol. 27, no. 1, pp. 11–20, 2011.
- J. D. Greenberg, G. Reed, J. M. Kremer et al., “Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry,” Annals of the Rheumatic Diseases, vol. 69, no. 2, pp. 380–386, 2010.
- C. Díaz-Lagares, R. Pérez-Alvarez, F. J. García-Hernández et al., “Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label,” Arthritis Research & Therapy, vol. 13, no. 4, article R112, 2011.